Search Results - "Thomopoulos, Thomas"

Refine Results
  1. 1

    Association of Age at Menopause and Duration of Reproductive Period With Depression After Menopause: A Systematic Review and Meta-analysis by Georgakis, Marios K, Thomopoulos, Thomas P, Diamantaras, Andreas-Antonios, Kalogirou, Eleni I, Skalkidou, Alkistis, Daskalopoulou, Stella S, Petridou, Eleni Th

    Published in JAMA psychiatry (Chicago, Ill.) (01-02-2016)
    “…Estrogens have neuroprotective and antidepressive effects; however, associations between indices of reduced endogenous estrogens and risk for postmenopausal…”
    Get more information
    Journal Article
  2. 2
  3. 3

    Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab by Papageorgiou, Sotirios G, Thomopoulos, Thomas P, Liaskas, Athanasios, Vassilakopoulos, Theodoros P

    Published in Cancers (10-04-2022)
    “…Although rituximab has revolutionized the treatment of diffuse large B-cell lymphoma (DLBCL), a significant proportion of patients experience refractory…”
    Get full text
    Journal Article
  4. 4

    Chronic Neutrophilic Leukemia: A Comprehensive Review of Clinical Characteristics, Genetic Landscape and Management by Thomopoulos, Thomas P, Symeonidis, Argiris, Kourakli, Alexandra, Papageorgiou, Sotirios G, Pappa, Vasiliki

    Published in Frontiers in oncology (14-04-2022)
    “…Chronic neutrophilic leukemia (CNL) represents a rare disease, that has been classified among the BCR/ABL-negative myeloproliferative neoplasms. The disease is…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Comorbidities and frailty predict outcome of patients with myelodysplastic syndromes. Should we integrate them in novel prognostic scoring systems? by Thomopoulos, Thomas P., Pappa, Vasiliki, Papageorgiou, Sotirios G.

    Published in Journal of geriatric oncology (01-09-2021)
    “…Prognosis of myelodysplastic syndromes (MDS) is based on scoring systems focusing on disease-related factors; however, several studies have shown that…”
    Get full text
    Journal Article
  7. 7
  8. 8
  9. 9

    Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine by Bouchla, Anthi, Thomopoulos, Thomas P, Papageorgiou, Sotirios G, Apostolopoulou, Christina, Loucari, Constantinos, Mpazani, Efthimia, Pappa, Vasiliki

    Published in Epigenomics (01-07-2021)
    “…5-Azacitidine (5-AZA) is widely used for the treatment of higher-risk myelodysplastic syndromes. However, response and survival rates vary considerably, while…”
    Get full text
    Journal Article
  10. 10
  11. 11
  12. 12
  13. 13

    Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications by Papageorgiou, Sotirios G., Thomopoulos, Thomas P., Katagas, Ioannis, Bouchla, Anthi, Pappa, Vassiliki

    “…Diffuse large B-cell lymphoma (DLBCL) represents a group of tumors characterized by substantial heterogeneity in terms of their pathological and biological…”
    Get full text
    Book Review Journal Article
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20